What's Happening?
Bayer has submitted an application to the FDA to modify the label of its chronic kidney disease (CKD) drug, Kerendia, to include patients with type 1 diabetes (T1D). Currently approved for type 2 diabetes (T2D), Kerendia is a mineralocorticoid receptor
antagonist (MRA) that has shown promise in reducing kidney damage markers in T1D patients. The FDA has granted a priority review to this application, with a decision expected within six months. This move follows the successful phase 3 FINE-ONE study, which demonstrated that Kerendia significantly decreased the urinary albumin-to-creatinine ratio, a key biomarker for kidney damage, in T1D patients. If approved, Kerendia would become the first new treatment in over 30 years for adults with CKD associated with T1D.
Why It's Important?
The potential approval of Kerendia for T1D patients represents a significant advancement in the treatment of CKD, a condition affecting approximately 850 million people globally. For Bayer, this expansion is crucial as it seeks to offset the impact of patent expirations and declining sales of other drugs like Xarelto and Eylea. The inclusion of T1D patients could enhance Kerendia's market presence, adding to its current success in treating CKD associated with T2D and heart failure. This strategic move could help Bayer maintain its competitive edge and achieve blockbuster status for Kerendia, with sales already showing significant growth.
What's Next?
If the FDA approves the label modification, Bayer will likely focus on marketing Kerendia to healthcare providers treating T1D patients with CKD. The company may also pursue further label extensions to include non-diabetic CKD patients, leveraging the results of the FIND-CKD study. This could broaden Kerendia's applicability and market reach, potentially leading to increased sales and further solidifying its position in the CKD treatment landscape.
